Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial-Reference-Cited by-同舟云学术

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial

Published:2008-05 Issue:5 Volume:19 Page:861-870
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Gluz O.,Nitz U.A.,Harbeck N.,Ting E.,Kates R.,Herr A.,Lindemann W.,Jackisch C.,Berdel W.E.,Kirchner H.,Metzner B.,Werner F.,Schütt G.,Frick M.,Poremba C.,Diallo-Danebrock R.,Mohrmann S.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/19/5/861/19445654/mdm551.pdf

Reference41 articles.

1. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update;Fisher;Cancer,1983

2. The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study;Montero;Cancer,2005

3. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Early Breast Cancer Trialists' Collaborative Group and EBCTCG;Lancet,2005

4. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy;Buzdar;Cancer,1992

5. High-dose chemotherapy with hematopoetic stem-cell rescue for high risk breast cancer;Rodenhuis;N Engl J Med,2003

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic Therapy Advances for HER2-Positive and Triple Negative Breast Cancer: What the Surgeon Needs to Know;Clinical Breast Cancer;2024-06

2. DDX58 deficiency leads to triple negative breast cancer chemotherapy resistance by inhibiting Type I IFN-mediated signalling apoptosis;Frontiers in Oncology;2024-03-14

3. Leveraging hypoxia in triple-negative breast cancer as a promising treatment strategy;Drug Discovery Today;2023-11

4. Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast Cancer;Biologics: Targets and Therapy;2023-09

5. DNA Damage Inducer Mitoxantrone Amplifies Synergistic Mild‐Photothermal Chemotherapy for TNBC via Decreasing Heat Shock Protein 70 Expression;Advanced Science;2023-04-17